Gb Sciences

Gb Sciences is a Las Vegas-based biopharmaceutical company founded in 2009 with a mission to bridge botanical medicine and modern drug discovery. Its core strategy utilizes the AI-powered PhAROS platform to deconvolute plant mixtures into defined, synergistic drug candidates. The company's key achievement is a patented, cannabinoid-based Parkinson's disease therapy with positive animal proof-of-concept data, now partnered for first-in-human trial sponsorship, alongside a broader preclinical pipeline.

The PhAROS Drug Discovery Platform uses AI and machine learning to predict synergistic combinations of plant-derived active ingredients, which are then validated through high-throughput screening in disease models to create defined 'minimum essential mixture' drug candidates.

Gb Sciences competes in crowded therapeutic areas but differentiates through its specialized AI platform for plant-based mixture optimization. It faces competition from large neurology-focused pharma, broad AI drug discovery companies, and cannabinoid pharmaceutical developers, but its niche focus on minimum essential mixtures is unique.